Brief: Can-Fite To Submit Ind For The Treatment Of Pancreatic Cancer Patients With Namodenoson
13/06/2023 12:06
June 13 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE TO SUBMIT IND FOR THE TREATMENT OF PANCREATIC
CANCER
PATIENTS WITH NAMODENOSON
Source text for Eikon: ID:nBwbl9HlHa
Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage